These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 14626985

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The Food and Drug Administration's regulation of prescription drug manufacturer speech: a First Amendment analysis.
    Evans GW, Friede AI, Pfizer Inc, New York, NY, USA.
    Food Drug Law J; 2003; 58(3):365-437. PubMed ID: 14626984
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Education or promotion?: Industry-sponsored continuing medical education (CME) as a center for the core/commercial speech debate.
    Chen P, Paul, Weiss, Rifkind, Wharton & Garrison LLP, New York, NY, USA.
    Food Drug Law J; 2003; 58(3):473-509. PubMed ID: 14626981
    [No Abstract] [Full Text] [Related]

  • 6. The future of off-label marketing regulations in the post-Sorrell era.
    Iraggi J.
    Seton Hall Law Rev; 2013; 43(3):1137-63. PubMed ID: 23802338
    [No Abstract] [Full Text] [Related]

  • 7. A global view of the First Amendment constraints of FDA.
    Carver KH.
    Food Drug Law J; 2008; 63(1):151-215. PubMed ID: 18561459
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
    Chaps NA.
    Issue Brief Health Policy Track Serv; 2010 Jan 04; ():1-31. PubMed ID: 20217914
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Manufacturers' promotion of off-label drug use: implications for drug safety.
    Zieve A, Carome MA.
    Expert Opin Drug Saf; 2016 Sep 04; 15(9):1149-51. PubMed ID: 27145440
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The First Amendment and federal court deference to the Food and Drug Administration: The Times They Are A-Changin'.
    Basile EM, Gross M.
    Food Drug Law J; 2004 Sep 04; 59(1):31-44. PubMed ID: 15190924
    [No Abstract] [Full Text] [Related]

  • 14. Caveat doctor.
    McCarthy M.
    Lancet; 1999 Aug 07; 354(9177):446. PubMed ID: 10465167
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Market exclusivity after a prescription to nonprescription drug switch: striking the right balance between innovation and competition.
    Kraushaar KJ.
    Food Drug Law J; 1999 Aug 07; 54(2):243-4. PubMed ID: 11758581
    [No Abstract] [Full Text] [Related]

  • 18. The new drug marketing: a consumer protection perspective.
    Woodward D.
    Food Drug Law J; 1996 Aug 07; 51(4):637-50. PubMed ID: 11797733
    [No Abstract] [Full Text] [Related]

  • 19. The FDA's graphic tobacco warnings and the first amendment.
    Orentlicher D.
    N Engl J Med; 2013 Jul 18; 369(3):204-6. PubMed ID: 23803137
    [No Abstract] [Full Text] [Related]

  • 20. The ongoing dialogue between the Food and Drug Administration and the Federal Trade Commission.
    Leary TB.
    Food Drug Law J; 2004 Jul 18; 59(2):209-15. PubMed ID: 15318392
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.